Stocks to watch today on the Paris Stock Exchange – Friday, October 28, 2022 – 10/28/2022 at 9:24 a.m.

(AOF) –

Air France KLM

Air France-KLM earned 460 million euros in net profit in the third quarter thanks to strong demand for air travel during the summer, even achieving higher turnover than the corresponding period of 2019 before the Covid. Its operating profit stands at 1.02 billion euros, a figure higher than the 844 million euros anticipated by a consensus established by the company. The Franco-Dutch airline posted a quarterly turnover of 8.11 billion euros, up 77.6%.


The aeronautical group will announce its results for the third quarter.


Danone published consolidated sales of 7.3 billion euros in the third quarter of 2022, up 9.5% like-for-like, with a price effect of +10.9% and a volume/mix effect of -1.4%. On a reported basis, revenue increased by 19.1%, thanks to the positive impact of exchange rates (+7.6%) resulting in particular from the appreciation against the euro of the US dollar and several Asian and Latin American currencies. Reported revenue also includes a positive organic contribution of +1.4% from hyperinflation countries.


Safran raised its 2022 revenue and free cash flow guidance, as third-quarter revenue grew 17.9% organically to $4.85 billion. euros, thanks in particular to the Propulsion and Aircraft Interiors activities. The group, which anticipated a turnover of between 18.2 and 18.4 billion euros in 2022, now expects it to be around 19 billion euros, forecasting growth in the activities of service and a rising dollar.

Saint Gobain

Saint-Gobain, specialist in building materials, published a turnover of 12.9 billion euros for the third quarter, up 13.4% compared to the same period a year earlier. Business grew in all geographies: +11.9% in Northern Europe, +10.5% in Southern Europe/Middle East/Africa, +14.2% in the Americas and +26.9% in Asia-Pacific.


The French laboratory Sanofi has revised its outlook for 2022 upwards, after achieving strong sales growth in the third quarter, still boosted by its flagship drug Dupixent, but also by vaccines. From July to the end of September, net profit from activities, which excludes exceptional items, jumped 32% to 3.6 billion euros (+17.7% at constant exchange rates). Net profit fell 10% to 2 billion euros, due to impairments, for sales up nearly 20%, to almost 12.5 billion euros.


In the first half of 2022-2023, Ubisoft’s net bookings fell by 2.6% to 699.4 million compared to the first half of 2021-2022. The company’s operating profit shows a loss of 215.3 million euros (139 million euros in non-IFRS). Ubisoft has confirmed its 2022-23 objectives, which are based on significant growth in net bookings and non-IFRS operating income of 400 million euros. The company has also implemented its cost optimization plan.


Valbiotis, a research and development company committed to scientific innovation, will present the significant preclinical results of its active substance TOTUM 448 non-medicinal active substance, based on plants, against metabolic damage to the liver, or fatty liver disease (NAFL and NASH) at the annual meeting of the American Association for the Study (AASLD) from November 4 to 8, 2022. These results demonstrate the effectiveness of TOTUM 448 from the early stages of these diseases, on steatosis, inflammation and fibrosis liverworts


Scroll to Top